20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Elanco Animal Health (ELAN) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Indianapolis, United States with about 9,400 employees. Its market capitalization is roughly $11 billion. In the fiscal year ended 2025-12-31, ELAN reported $4.7B in revenue and ($232M) in net income.
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
Interactive charts & full statements → Open the ELAN valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $5.0B | $4.7B | $4.4B | $4.4B | $4.4B | $4.8B | $3.3B | $3.1B | $3.1B | $2.9B | $2.9B | $2.9B |
| Gross Profit | $2.6B | $2.0B | $1.9B | $1.9B | $2.0B | $2.1B | $1.2B | $1.4B | $1.3B | $1.2B | $1.3B | $1.2B |
| Gross Margin % | 52.6% | 43.5% | 43.0% | 43.9% | 44.7% | 43.6% | 38.1% | 45.6% | 42.2% | 40.6% | 45.8% | 41.7% |
| Operating Income (EBIT) | — | $252M | $251M | $326M | $384M | $304M | ($77M) | $370M | $314M | $142M | $283M | $5M |
| Operating Margin % | — | 5.3% | 5.7% | 7.4% | 8.7% | 6.4% | -2.4% | 12.0% | 10.2% | 4.9% | 9.7% | 0.2% |
| Net Income | ($199M) | ($232M) | $338M | ($1.2B) | ($78M) | ($483M) | ($560M) | $68M | $86M | ($311M) | ($48M) | ($211M) |
| Net Margin % | -4.0% | -4.9% | 7.6% | -27.9% | -1.8% | -10.1% | -17.1% | 2.2% | 2.8% | -10.8% | -1.6% | -7.2% |
| EBITDA | — | $676M | $1.5B | ($224M) | $866M | $409M | $1M | $472M | $440M | $86M | $232M | ($23M) |
| Earnings Per Share (EPS) | $-0.41 | $-0.47 | $0.68 | $-2.50 | $-0.16 | $-0.99 | $-1.27 | $0.18 | $0.28 | $-0.87 | $-0.13 | $-0.59 |
| Shares Outstanding (M) | — | 496M | 497M | 492M | 488M | 487M | 441M | 370M | 314M | 356M | 356M | 356M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.4B | $1.4B | $1.1B | $1.1B | $1.2B | $1.2B | $1.0B | $1.0B | $1.2B |
| Gross Profit | $798M | $785M | $450M | $607M | $577M | $556M | $389M | $405M | $558M |
| Gross Margin % | 58.3% | 57.3% | 39.3% | 53.4% | 46.5% | 46.6% | 38.1% | 39.3% | 47.1% |
| Operating Income (EBIT) | — | $307M | $19M | $27M | $85M | $121M | $8M | ($5M) | $115M |
| Operating Margin % | — | 22.4% | 1.7% | 2.4% | 6.9% | 10.1% | 0.8% | -0.5% | 9.7% |
| Net Income | $54M | $57M | ($276M) | ($34M) | $11M | $67M | ($8M) | $364M | ($50M) |
| Net Margin % | 4.0% | 4.2% | -24.1% | -3.0% | 0.9% | 5.6% | -0.8% | 35.3% | -4.2% |
| EBITDA | — | $316M | $6M | $178M | $264M | $274M | $175M | $814M | $195M |
| Earnings Per Share (EPS) | $0.11 | $0.11 | $-0.56 | $-0.07 | $0.02 | $0.13 | $-0.02 | $0.73 | $-0.10 |
| Shares Outstanding (M) | — | 506M | 497M | 497M | 500M | 499M | 494M | 498M | 494M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $617M | $560M | $541M | $271M | $452M | $483M | ($41M) | $224M | $487M | $174M | $156M | $7M |
| Capital Expenditures (CapEx) | $238M | $276M | $147M | $154M | $184M | $197M | $311M | $197M | $134M | $99M | $110M | $100M |
| Free Cash Flow (FCF) | $379M | $284M | $394M | $117M | $268M | $286M | ($352M) | $27M | $353M | $75M | $46M | ($94M) |
| FCF Margin % | 7.5% | 6.0% | 8.9% | 2.6% | 6.1% | 6.0% | -10.8% | 0.9% | 11.5% | 2.6% | 1.6% | -3.2% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $277M | $13M | $108M | $219M | $237M | ($4M) | $177M | $162M | $200M |
| Capital Expenditures (CapEx) | $33M | $51M | $62M | $92M | $57M | $65M | $53M | $42M | $34M |
| Free Cash Flow (FCF) | $244M | ($38M) | $46M | $127M | $180M | ($69M) | $124M | $120M | $166M |
| FCF Margin % | 17.8% | -2.8% | 4.0% | 11.2% | 14.5% | -5.8% | 12.2% | 11.7% | 14.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $13.6B | $13.4B | $12.6B | $14.4B | $15.5B | $16.5B | $17.7B | $9.0B | $9.0B | $8.9B | $8.1B |
| Cash & Cash Equivalents | $530M | $545M | $468M | $352M | $345M | $638M | $495M | $334M | $475M | $323M | $259M |
| Total Liabilities | $7.0B | $6.8B | $6.5B | $8.1B | $8.2B | $9.0B | $9.2B | $3.4B | $3.8B | $1.1B | $1.1B |
| Total Debt (Short + Long-Term) | $3.9B | $4.0B | $4.3B | $5.8B | $5.8B | $6.3B | $6.1B | $2.4B | $2.5B | $0M | $0M |
| Total Shareholders' Equity | $6.6B | $6.5B | $6.1B | $6.2B | $7.3B | $7.5B | $8.5B | $5.5B | $5.2B | $7.8B | $7.0B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ELAN viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms